Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 571

1.

Circulating antibodies against Epstein-Barr virus (EBV) and p53 in EBV-positive and -negative gastric cancer.

Camargo MC, Kim KM, Matsuo K, Torres J, Liao LM, Morgan D, Michel A, Waterboer T, Song M, Gulley ML, Dominguez RL, Yatabe Y, Kim S, Cortes-Martinez G, Lissowska J, Zabaleta J, Pawlita M, Rabkin CS.

Cancer Epidemiol Biomarkers Prev. 2019 Nov 12. pii: cebp.0790.2019. doi: 10.1158/1055-9965.EPI-19-0790. [Epub ahead of print]

PMID:
31719065
2.

Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing.

Mikubo M, Seto K, Kitamura A, Nakaguro M, Hattori Y, Maeda N, Miyazaki T, Watanabe K, Murakami H, Tsukamoto T, Yamada T, Fujita S, Masago K, Ramkissoon S, Ross JS, Elvin J, Yatabe Y.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33409-4. doi: 10.1016/j.jtho.2019.09.081. [Epub ahead of print]

PMID:
31605798
3.

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer.

Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T.

Ann Oncol. 2019 Sep 25. pii: mdz399. doi: 10.1093/annonc/mdz399. [Epub ahead of print]

PMID:
31553438
4.

Dynamics of Circulating Tumor Cells Early After Targeting Therapy to Human EGFR-mutated Lung Cancers and HER2 Gene-amplified Gastric Cancers in Mice.

Ito A, Nakanishi H, Yoshimura M, Ito S, Sakao Y, Kodera Y, Yatabe Y, Kaneda N.

Anticancer Res. 2019 Sep;39(9):4711-4720. doi: 10.21873/anticanres.13653.

PMID:
31519570
5.

Long-term complete response in a patient with postoperative recurrent ALK-rearranged lung adenocarcinoma treated with crizotinib: A case report.

Kosaka T, Yajima T, Yamaki E, Nakazawa S, Tomizawa K, Onozato R, Yamazaki A, Hirato J, Yatabe Y, Shimizu K, Mogi A, Shirabe K.

Mol Clin Oncol. 2019 Sep;11(3):309-312. doi: 10.3892/mco.2019.1892. Epub 2019 Jul 3.

6.

Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features.

Watari J, Mitani S, Ito C, Tozawa K, Tomita T, Oshima T, Fukui H, Kadowaki S, Natsume S, Senda Y, Tajika M, Hara K, Yatabe Y, Shimizu Y, Muro K, Morimoto T, Hirota S, Das KM, Miwa H.

Sci Rep. 2019 Jul 19;9(1):10526. doi: 10.1038/s41598-019-46167-y.

7.

Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women.

Wong JYY, Zhang H, Hsiung CA, Shiraishi K, Yu K, Matsuo K, Wong MP, Hong YC, Wang J, Seow WJ, Wang Z, Song M, Kim HN, Chang IS, Chatterjee N, Hu W, Wu C, Mitsudomi T, Zheng W, Kim JH, Seow A, Caporaso NE, Shin MH, Chung LP, An SJ, Wang P, Yang Y, Zheng H, Yatabe Y, Zhang XC, Kim YT, Cai Q, Yin Z, Kim YC, Bassig BA, Chang J, Ho JCM, Ji BT, Daigo Y, Ito H, Momozawa Y, Ashikawa K, Kamatani Y, Honda T, Hosgood HD, Sakamoto H, Kunitoh H, Tsuta K, Watanabe SI, Kubo M, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Shi J, Song L, Hua X, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wei F, Matsuda F, Su J, Kim YH, Oh IJ, Song F, Su WC, Chen YM, Chang GC, Chen KY, Huang MS, Chien LH, Xiang YB, Park JY, Kweon SS, Chen CJ, Lee KM, Blechter B, Li H, Gao YT, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Wang WC, Chung CC, Burdett L, Yeager M, Hutchinson A, Berndt SI, Wu W, Pang H, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Zhu M, Chen CH, Yang TY, Xu J, Guan P, Tan W, Wang CL, Hsin M, Sit KY, Ho J, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Lin CC, Park IK, Xu P, Wang Y, He Q, Perng RP, Chen CY, Vermeulen R, Wu J, Lim WY, Chen KC, Li YJ, Li J, Chen H, Yu CJ, Jin L, Chen TY, Jiang SS, Liu J, Yamaji T, Hicks B, Wyatt K, Li SA, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Li X, Ren Y, Cui P, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Chen Y, Yang K, Jiang G, Fei K, Wu G, Lin HC, Chen HL, Fang YH, Tsai FY, Hsieh WS, Yu J, Stevens VL, Laird-Offringa IA, Marconett CN, Rieswijk L, Chao A, Yang PC, Shu XO, Wu T, Wu YL, Lin D, Chen K, Zhou B, Huang YC, Kohno T, Shen H, Chanock SJ, Rothman N, Lan Q.

Genomics. 2019 Jul 12. pii: S0888-7543(19)30112-0. doi: 10.1016/j.ygeno.2019.07.008. [Epub ahead of print]

PMID:
31306748
8.

Recurrence patterns and lifetime performance of parity 1 sows in breeding herds with different weaning-to-first-mating intervals.

Yatabe Y, Iida R, Pi├▒eiro C, Koketsu Y.

Porcine Health Manag. 2019 Jun 28;5:15. doi: 10.1186/s40813-019-0122-0. eCollection 2019.

9.

Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.

Mishima S, Taniguchi H, Akagi K, Baba E, Fujiwara Y, Hirasawa A, Ikeda M, Maeda O, Muro K, Nishihara H, Nishiyama H, Takano T, Tsuchihara K, Yatabe Y, Kodera Y, Yoshino T.

Int J Clin Oncol. 2019 Jul 8. doi: 10.1007/s10147-019-01498-8. [Epub ahead of print]

PMID:
31286289
10.

Successful salvage surgery following multimodal therapy in a patient who harboured ALK-rearranged advanced lung adenocarcinoma with multiple organ metastases.

Horio Y, Mizuno T, Sakao Y, Inaba Y, Yatabe Y, Hida T.

Respirol Case Rep. 2019 Jun 24;7(7):e00451. doi: 10.1002/rcr2.451. eCollection 2019 Oct.

11.

A long-term survival case of Sister Mary Joseph's nodule caused by colon cancer and treated with a multidisciplinary approach.

Iwata Y, Kinoshita T, Kimura K, Komori K, Hayashi D, Akazawa T, Shigeyoshi I, Tsutsuyama M, Kawakami J, Ouchi A, Natsume S, Uemura N, Ito Y, Misawa K, Senda Y, Abe T, Ito S, Tajika M, Yatabe Y, Yoshida K, Shimizu Y.

Nagoya J Med Sci. 2019 May;81(2):325-329. doi: 10.18999/nagjms.81.2.325.

12.

Helicobacter pylori (HP) infection alone, but not HP-induced atrophic gastritis, increases the risk of gastric lymphoma: a case-control study in Japan.

Ishikura N, Usui Y, Ito H, Kasugai Y, Oze I, Kato S, Yatabe Y, Nakamura S, Matsuo K.

Ann Hematol. 2019 Aug;98(8):1981-1987. doi: 10.1007/s00277-019-03721-y. Epub 2019 Jun 8.

PMID:
31177299
13.

Epithelioid hemangioendothelioma of the parotid gland: a case report.

Koide Y, Sasaki E, Masago K, Fujita S, Beppu S, Nishikawa D, Suzuki H, Hasegawa Y, Yatabe Y, Hanai N.

Int Cancer Conf J. 2018 Nov 29;8(1):39-42. doi: 10.1007/s13691-018-0351-0. eCollection 2019 Jan.

PMID:
31149545
14.

Long-term outcomes of metachronous neoplasms in the ileal pouch and rectum after surgical treatment in patients with familial adenomatous polyposis.

Tajika M, Tanaka T, Ishihara M, Hirayama Y, Oonishi S, Mizuno N, Kuwahara T, Okuno N, Matsumoto S, Ooshiro T, Kinoshita T, Komori K, Bhatia V, Hara K, Yatabe Y, Niwa Y.

Endosc Int Open. 2019 May;7(5):E691-E698. doi: 10.1055/a-0849-9465. Epub 2019 May 8.

15.

Immunocytochemistry for predictive biomarker testing in lung cancer cytology.

Jain D, Nambirajan A, Borczuk A, Chen G, Minami Y, Moreira AL, Motoi N, Papotti M, Rekhtman N, Russell PA, Savic Prince S, Yatabe Y, Bubendorf L; IASLC Pathology Committee.

Cancer Cytopathol. 2019 May;127(5):325-339. doi: 10.1002/cncy.22137. Epub 2019 May 3. Review.

PMID:
31050216
16.

Usefulness of septal thickness measurement on endoscopic ultrasound as a predictor of malignancy of branched-duct and mixed-type intraductal papillary mucinous neoplasm of the pancreas.

Iwaya H, Hijioka S, Mizuno N, Kuwahara T, Okuno N, Tajika M, Tanaka T, Ishihara M, Hirayama Y, Onishi S, Ito A, Kuraoka N, Matsumoto S, Polmanee P, Shimizu Y, Yatabe Y, Niwa Y, Tamada K, Ido A, Hara K.

Dig Endosc. 2019 Nov;31(6):672-681. doi: 10.1111/den.13408. Epub 2019 Apr 29.

PMID:
30920028
17.

Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung.

Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J, Yatabe Y, Zhang J, Futreal PA, Fowler J, Fujimoto J, Ehli EA, Hawk ET, Wistuba II, Kadara H, Scheet P.

EBioMedicine. 2019 Apr;42:296-303. doi: 10.1016/j.ebiom.2019.03.020. Epub 2019 Mar 21.

18.

Important cytological findings for distinction between follicular variant and conventional papillary thyroid carcinoma, including noninvasive follicular thyroid tumors with papillary-like nuclear features.

Koshikawa T, Fujita N, Ueda N, Ota Y, Sasaki E, Murakami Y, Hosoda W, Yatabe Y, Hanai N, Higuchi M, Hirokawa M, Miyauchi A.

Endocr J. 2019 May 28;66(5):475-483. doi: 10.1507/endocrj.EJ18-0525. Epub 2019 Mar 14.

19.

Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately.

Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Yane K, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Sakaguchi M, Ishii H, Kojima Y, Matsuo K, Yoshitomi H, Nakamori S, Yanagimoto H, Yatabe Y, Furuse J, Mizuno N.

Ann Surg Oncol. 2019 May;26(5):1385-1393. doi: 10.1245/s10434-019-07252-8. Epub 2019 Mar 12.

PMID:
30863939
20.

Detection of circulating tumor cells in drainage venous blood from colorectal cancer patients using a new filtration and cytology-based automated platform.

Tsutsuyama M, Nakanishi H, Yoshimura M, Oshiro T, Kinoshita T, Komori K, Shimizu Y, Ichinosawa Y, Kinuta S, Wajima K, Sakakibara Y, Yatabe Y, Ito S, Kodera Y.

PLoS One. 2019 Feb 27;14(2):e0212221. doi: 10.1371/journal.pone.0212221. eCollection 2019.

21.

Anaplastic lymphoma kinase expression in small-cell lung cancer.

Kondoh C, Horio Y, Hayashi Y, Ebi H, Hida T, Hasegawa Y, Yatabe Y.

Histopathology. 2019 Jul;75(1):20-28. doi: 10.1111/his.13842. Epub 2019 May 23.

PMID:
30790327
22.

Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.

Honda K, Kadowaki S, Kato K, Hanai N, Hasegawa Y, Yatabe Y, Muro K.

Invest New Drugs. 2019 Aug;37(4):791-795. doi: 10.1007/s10637-019-00742-2. Epub 2019 Feb 21.

PMID:
30790150
23.

Emergence of artistic talent in progressive nonfluent aphasia: a case report.

Hamauchi A, Hidaka Y, Kitamura I, Yatabe Y, Hashimoto M, Yonehara T, Fukuhara R, Ikeda M.

Psychogeriatrics. 2019 Nov;19(6):601-604. doi: 10.1111/psyg.12437. Epub 2019 Feb 19.

PMID:
30780199
24.

Salvage surgery for small cell lung cancer after chemoradiotherapy.

Nakanishi K, Mizuno T, Sakakura N, Kuroda H, Shimizu J, Hida T, Yatabe Y, Sakao Y.

Jpn J Clin Oncol. 2019 Apr 1;49(4):389-392. doi: 10.1093/jjco/hyz010.

PMID:
30753585
25.

Evaluation of lobar lymph node metastasis in non-small cell lung carcinoma using modified total lesion glycolysis.

Dejima H, Kuroda H, Oya Y, Sakakura N, Inaba Y, Tamaki T, Yatabe Y, Sakao Y.

J Thorac Dis. 2018 Dec;10(12):6932-6941. doi: 10.21037/jtd.2018.11.40.

26.

The overall survival of breast cancer patients without adjuvant therapy.

Onishi S, Sawaki M, Ishiguro J, Kataoka A, Iwase M, Sugino K, Adachi Y, Gondo N, Kotani H, Yoshimura A, Hattori M, Matsuo K, Yatabe Y, Iwata H.

Surg Today. 2019 Jul;49(7):610-620. doi: 10.1007/s00595-019-01775-z. Epub 2019 Feb 7.

PMID:
30730005
27.

The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation.

Mitani S, Taniguchi H, Sugiyama K, Masuishi T, Honda K, Narita Y, Kadowaki S, Ura T, Ando M, Tajika M, Yatabe Y, Muro K.

Ther Adv Med Oncol. 2019 Jan 12;11:1758835918820298. doi: 10.1177/1758835918820298. eCollection 2019.

28.

Prediction of pathological margin status using preoperative contrast-enhanced MRI in patients with early breast cancer who underwent skin-sparing mastectomy.

Kataoka A, Sawaki M, Okumura S, Onishi S, Iwase M, Sugino K, Ishiguro J, Gondo N, Kotani H, Yoshimura A, Hattori M, Sasaki E, Yatabe Y, Yoshimura K, Omi K, Iwata H.

Breast J. 2019 Mar;25(2):202-206. doi: 10.1111/tbj.13194. Epub 2019 Jan 30.

PMID:
30697867
29.

Importance of avoiding surgery delays after initial discovery of suspected non-small-cell lung cancer in clinical stage IA patients.

Kuroda H, Sugita Y, Ohya Y, Yoshida T, Arimura T, Sakakura N, Hida T, Yatabe Y, Sakao Y.

Cancer Manag Res. 2018 Dec 20;11:107-115. doi: 10.2147/CMAR.S180757. eCollection 2019.

30.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
31.

[Pathological Diagnosis of MSI-H Tumors].

Yatabe Y.

Gan To Kagaku Ryoho. 2018 Nov;45(11):1582-1586. Japanese.

PMID:
30449842
32.

Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.

Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y, Hida T.

Lung Cancer. 2018 Nov;125:212-217. doi: 10.1016/j.lungcan.2018.10.001. Epub 2018 Oct 3.

PMID:
30429022
33.

Detection of abundant megakaryocytes in pulmonary artery blood in lung cancer patients using a microfluidic platform.

Dejima H, Nakanishi H, Kuroda H, Yoshimura M, Sakakura N, Ueda N, Ohta Y, Tanaka R, Mori S, Yoshida T, Hida T, Sawabata N, Yatabe Y, Sakao Y.

Lung Cancer. 2018 Nov;125:128-135. doi: 10.1016/j.lungcan.2018.09.011. Epub 2018 Sep 16.

PMID:
30429010
34.

Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1.

Hakiri S, Fukui T, Mori S, Kawaguchi K, Nakamura S, Ozeki N, Kato T, Goto M, Yatabe Y, Yokoi K.

Ann Thorac Surg. 2019 Feb;107(2):418-424. doi: 10.1016/j.athoracsur.2018.08.037. Epub 2018 Oct 9.

PMID:
30312607
35.

Spontaneous regression of lung squamous cell carcinoma with synchronous mediastinal progression: A case report.

Matsui T, Mizuno T, Kuroda H, Sakakura N, Arimura T, Yatabe Y, Sakao Y.

Thorac Cancer. 2018 Dec;9(12):1778-1781. doi: 10.1111/1759-7714.12892. Epub 2018 Oct 11.

36.

Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET.

Hijioka S, Sakuma K, Aoki M, Mizuno N, Kuwahara T, Okuno N, Hara K, Yatabe Y.

Cancer Chemother Pharmacol. 2019 Jan;83(1):43-52. doi: 10.1007/s00280-018-3700-y. Epub 2018 Oct 11.

PMID:
30310970
37.

Inherited lung cancer syndromes targeting never smokers.

Yamamoto H, Yatabe Y, Toyooka S.

Transl Lung Cancer Res. 2018 Aug;7(4):498-504. doi: 10.21037/tlcr.2018.06.01. Review.

38.

Contribution of smoking habit to the prognosis of stage I KRAS-mutated non-small cell lung cancer.

Kuroda H, Yoshida T, Arimura T, Mizuno T, Sakakura N, Yatabe Y, Sakao Y.

Cancer Biomark. 2018;23(3):419-426. doi: 10.3233/CBM-181483.

PMID:
30223391
39.

Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site.

Hasegawa H, Ando M, Yatabe Y, Mitani S, Honda K, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Ura T, Muro K.

Clin Oncol (R Coll Radiol). 2018 Oct;30(10):667-673. doi: 10.1016/j.clon.2018.06.012. Epub 2018 Jul 6.

PMID:
30196846
40.

Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment.

Furuta H, Uemura T, Yoshida T, Kobara M, Yamaguchi T, Watanabe N, Shimizu J, Horio Y, Kuroda H, Sakao Y, Yatabe Y, Hida T.

Anticancer Res. 2018 Sep;38(9):5231-5237. doi: 10.21873/anticanres.12847.

PMID:
30194172
41.

Simultaneous resections of left lung cancer and esophageal schwannoma using video-assisted thoracoscopic surgery: A case report.

An B, Abe T, Uemura N, Higaki E, Hosoi T, Kuroda H, Matsui T, Ishihara M, Kurita Y, Yatabe Y, Shimizu Y.

Asian J Endosc Surg. 2019 Jul;12(3):348-353. doi: 10.1111/ases.12643. Epub 2018 Aug 30.

PMID:
30168282
42.

Sinonasal squamous cell carcinoma and EGFR mutations: a molecular footprint of a benign lesion.

Sasaki E, Nishikawa D, Hanai N, Hasegawa Y, Yatabe Y.

Histopathology. 2018 Dec;73(6):953-962. doi: 10.1111/his.13732. Epub 2018 Oct 23.

PMID:
30117182
43.

Fibrolamellar Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Multidisciplinary Therapy.

Tanaka H, Hijioka S, Iwaya H, Mizuno N, Kuwahara T, Okuno N, Ito A, Kuraoka N, Matsumoto S, Obata M, Kurita Y, Yasuda M, Shimizu Y, Kuroda H, Sato Y, Haneda M, Sasaki E, Yatabe Y, Hara K.

Intern Med. 2018 Dec 15;57(24):3537-3543. doi: 10.2169/internalmedicine.1243-18. Epub 2018 Aug 10.

44.

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target.

Song KA, Hosono Y, Turner C, Jacob S, Lochmann TL, Murakami Y, Patel NU, Ham J, Hu B, Powell KM, Coon CM, Windle BE, Oya Y, Koblinski JE, Harada H, Leverson JD, Souers AJ, Hata AN, Boikos S, Yatabe Y, Ebi H, Faber AC.

Clin Cancer Res. 2018 Nov 15;24(22):5658-5672. doi: 10.1158/1078-0432.CCR-18-0304. Epub 2018 Aug 7.

PMID:
30087143
45.

Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement.

Seto K, Kuroda H, Yoshida T, Sakata S, Mizuno T, Sakakura N, Hida T, Yatabe Y, Sakao Y.

Cancer Manag Res. 2018 Jul 18;10:2117-2124. doi: 10.2147/CMAR.S147569. eCollection 2018.

46.

Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes.

Terada M, Adachi Y, Sawaki M, Hattori M, Yoshimura A, Naomi G, Kotani H, Iwase M, Kataoka A, Onishi S, Sugino K, Mori M, Horisawa N, Sasaki E, Yatabe Y, Iwata H.

Breast Cancer Res Treat. 2018 Nov;172(1):1-7. doi: 10.1007/s10549-018-4898-4. Epub 2018 Jul 20. Review.

PMID:
30030707
47.

Targeting minimal residual disease after surgery with molecular targeted therapy: the real path to a cure?

Masago K, Fujita S, Yatabe Y.

J Thorac Dis. 2018 Jun;10(Suppl 17):S1982-S1985. doi: 10.21037/jtd.2018.04.155. No abstract available.

48.

Inflammation Flare and Radiation Necrosis Around a Stereotactic Radiotherapy-Pretreated Brain Metastasis Site After Nivolumab Treatment.

Furuta H, Yoshida T, Natsume A, Hida T, Yatabe Y.

J Thorac Oncol. 2018 Dec;13(12):1975-1978. doi: 10.1016/j.jtho.2018.07.005. Epub 2018 Jul 12. No abstract available.

PMID:
30017830
49.

Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer.

Kuraoka N, Hara K, Terai S, Yatabe Y, Horio Y.

Endoscopy. 2018 Sep;50(9):E259-E261. doi: 10.1055/a-0640-2392. Epub 2018 Jul 3. No abstract available.

PMID:
29969801
50.

Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Masago K, Irie K, Fujita S, Imamichi F, Okada Y, Katakami N, Fukushima S, Yatabe Y.

Oncology. 2018;95(4):251-256. doi: 10.1159/000490177. Epub 2018 Jun 14.

PMID:
29902802

Supplemental Content

Loading ...
Support Center